Real-world treatment patterns and healthcare resource use in patients with acute myeloid leukemia in Western Europe

2021 ◽  
Author(s):  
Madhusudan Kabra ◽  
Luana Margotto ◽  
Fil Manuguid
Keyword(s):  
Acute Myeloid Leukemia ◽  
Induction Therapy ◽  
Real World ◽  
Myeloid Leukemia ◽  
Western Europe ◽  
Healthcare Resource ◽  
Treatment Patterns ◽  
Cross Sectional ◽  
Use Of Resources ◽  
Acute Myeloid

Aim: Assess treatment patterns and healthcare resource utilization (HRU) in patients with treatment-naive (TN) or relapsed/refractory (R/R) acute myeloid leukemia (AML) in Europe. Patients & methods: Cross-sectional, retrospective, web-based survey of AML-treating healthcare professionals (HCPs) in 12 European countries. Results: 320 HCPs provided information on 1280 TN or R/R patients. Patients ineligible versus eligible for intensive induction therapy required more general practitioner visits (4.1 vs 2.4), more uses of healthcare-related transport (6.9 vs 4.5), but less hospitalization (11.4 vs 27.5 days). Differences were observed in HRU and treatment patterns across countries. Conclusions: This analysis of ‘real-world’ patients with TN or R/R AML in Europe demonstrates substantial healthcare use, including higher use of resources in patients ineligible for intensive induction therapy.

scholarly journals Treatment patterns in patients with acute myeloid leukemia in the United States: a cross-sectional, real-world survey

2019 ◽  
Vol 35 (5) ◽  
pp. 927-935 ◽  
Author(s):  
Bruno C. Medeiros ◽  
Bhavik J. Pandya ◽  
Anna Hadfield ◽  
James Pike ◽  
Samuel Wilson ◽  
...  
Keyword(s):  
United States ◽  
Acute Myeloid Leukemia ◽  
Real World ◽  
Myeloid Leukemia ◽  
The United States ◽  
Treatment Patterns ◽  
Cross Sectional ◽  
World Survey ◽  
Acute Myeloid

Treatment patterns and comparative analysis of non-intensive regimens in elderly acute myeloid leukemia patients—a real-world experience from India

2019 ◽  
Vol 98 (4) ◽  
pp. 881-888 ◽  
Author(s):  
Govind B. Kanakasetty ◽  
Chethan R ◽  
Lakshmaiah K C ◽  
Lokanatha Dasappa ◽  
Linu Abraham Jacob ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Comparative Analysis ◽  
Real World ◽  
Myeloid Leukemia ◽  
Treatment Patterns ◽  
Acute Myeloid

A retrospective, real-world population-based analysis of treatment patterns and outcomes in adult patients with relapsed/refractory acute myeloid leukemia in Alberta, Canada.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e18505-e18505
Author(s):  
Michelle N. Geddes ◽  
Lalit Saini ◽  
Fei Fei Liu ◽  
Dimas Yusuf ◽  
Kiersten Schwann ◽  
...  
Keyword(s):  
Overall Survival ◽  
Acute Myeloid Leukemia ◽  
Cancer Registry ◽  
Real World ◽  
Medical Records ◽  
Myeloid Leukemia ◽  
Intensive Therapy ◽  
Population Based ◽  
Treatment Patterns ◽  
Acute Myeloid

e18505 Background: In order to describe the impact of future targeted therapies on treatment outcomes of patients (pts) with relapsed and/or refractory (RR) acute myeloid leukemia (AML), a better understanding of the clinical management pathway in these pts is needed. We therefore evaluated the treatment patterns and associated outcomes in a real-world cohort of pts with RR-AML using a population-based cancer registry and patient medical records. Methods: Pts newly diagnosed wih AML between January 2013 and December 2016, aged ≥ 18 years were identified from the provincial-wide Alberta Cancer Registry (ACR). Data for pts who met the criteria for RR-AML were assessed by hematologists and were extracted from medical records. RR-AML pts were then categorized as: receiving intensive therapy (IT); receiving non-intensive therapy (NIT); or treated with best-supportive care (BSC) following a diagnosis of RR-AML. Results: 572 AML pts were identified from the ACR, of which 199 met criteria for RR-AML and were included in the analysis (124 males, 75 females; median age at diagnosis of RR-AML 66.8 years; median follow-up 4.7 months). In this RR-AML cohort, 26 (13%) pts received ≥ 2 lines of prior therapy. Unadjusted median overall survival (mOS) was 5.3 months, with a 12-month overall survival rate of 29.6% (95% CI 29.0–30.3%) from the time of RR. Following RR, 46 (23%) pts received IT, 65 (33%) pts were treated with NIT, and 88 (44%) pts received BSC, with unadjusted mOS of 13.8, 9.4, and 2.1 months, respectively ( P < 0.001). When stratified by European LeukemiaNet risk classification at diagnosis, unadjusted mOS was 12.4, 4.7, and 4.0 months for favorable risk, intermediate risk, and adverse risk groups, respectively ( P < 0.01). Conclusions: This retrospective, real-world study in Alberta Canada confirms the poor prognosis reported to date in the RR-AML population. Notably, a large proportion of pts received BSC which was associated with dismal survival outcomes. These data also highlight that effective and tolerable alternatives to current treatment options are urgently needed.

Sign in / Sign up

Export Citation Format

Share Document